Moaath K Mustafa Ali

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8755304/publications.pdf

Version: 2024-02-01

1040056 996975 34 266 9 15 citations g-index h-index papers 38 38 38 470 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Long-term peripheral neuropathy symptoms in breast cancer survivors. Breast Cancer Research and Treatment, 2017, 166, 519-526.	2.5	49
2	Hospital admission trends due to respiratory diseases in England and Wales between 1999 and 2019: an ecologic study. BMC Pulmonary Medicine, 2021, 21, 356.	2.0	26
3	Hospital Admissions Due to Ischemic Heart Diseases and Prescriptions of Cardiovascular Diseases Medications in England and Wales in the Past Two Decades. International Journal of Environmental Research and Public Health, 2021, 18, 7041.	2.6	24
4	Is Hashimoto's thyroiditis a risk factor for medullary thyroid carcinoma? Our experience and a literature review. Endocrine, 2015, 48, 629-636.	2.3	15
5	Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 797-803.	0.4	15
6	Chimeric antigen receptor Tâ€cell therapy after allogeneic stem cell transplant for relapsed/refractory large Bâ€cell lymphoma. British Journal of Haematology, 2021, 192, 212-216.	2.5	14
7	Prevalence and correlates of patient-reported symptoms and comorbidities in breast cancer survivors at a tertiary center. Journal of Cancer Survivorship, 2017, 11, 743-750.	2.9	13
8	Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment. Platelets, 2015, 26, 491-494.	2.3	11
9	Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 3-4.	1.4	11
10	Trends in Hospital Admissions Due to Neoplasms in England and Wales between 1999 and 2019: An Ecological Study. International Journal of Environmental Research and Public Health, 2022, 19, 8054.	2.6	11
11	The impact of bridging therapy prior to CD19â€directed chimeric antigen receptor Tâ€cell therapy in patients with large Bâ€cell lymphoma. British Journal of Haematology, 2021, 195, 405-412.	2.5	10
12	Type-B lactic acidosis associated with progressive multiple myeloma. Journal of King Abdulaziz University, Islamic Economics, 2015, 36, 239-242.	1.1	9
13	Hemophagocytic Lymphohistiocytosis in a Patient With Hodgkin lymphoma and Concurrent EBV, CMV, and Candida Infections. Journal of Investigative Medicine High Impact Case Reports, 2017, 5, 232470961668451.	0.6	9
14	The prevalence of isolated growth hormone deficiency among children of short stature in Jordan and its relationship with consanguinity. Clinical Endocrinology, 2014, 81, 876-882.	2.4	8
15	Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma. Leukemia and Lymphoma, 2022, 63, 1339-1347.	1.3	6
16	Increased body mass index is a risk factor for acute promyelocytic leukemia. EJHaem, 2021, 2, 33-39.	1.0	5
17	Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study. Frontiers in Oncology, 2022, 12, 858202.	2.8	5
18	The Trend of Combined Modality Treatment and its Outcomes in Elderly Patients With Primary CNS Lymphoma: A 12-year Population-based Analysis Using Propensity Score. Anticancer Research, 2022, 42, 1867-1877.	1.1	4

#	Article	IF	CITATIONS
19	Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2017, 23, 776-781.	2.0	3
20	Hospitalization and Post-hospitalization Outcomes Among Teaching Internal Medicine, Employed Hospitalist, and Locum Tenens Hospitalist Services in a Tertiary Center: a Prospective Cohort Study. Journal of General Internal Medicine, 2021, 36, 3040-3051.	2.6	3
21	Pseudo-Allogeneic CAR-T Therapy after Allogeneic Stem Cell Transplantation in Relapsed/Refractory B-Cell NHL. Blood, 2020, 136, 22-23.	1.4	3
22	Impact of IDH1 c.315C>T SNP on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study. Frontiers in Oncology, 2022, 12, 804961.	2.8	3
23	Impact of FLT3-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study. Biology, 2022, 11, 916.	2.8	3
24	Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication. Oncotarget, 2021, 12, 1763-1779.	1.8	2
25	Patterns of treatment and their outcomes in primary breast lymphoma; a comprehensive population-based analysis. Breast Cancer, 2022, 29, 1022-1031.	2.9	2
26	Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era. Blood, 2015, 126, 1520-1520.	1.4	1
27	The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma. Blood, 2020, 136, 7-8.	1.4	1
28	Intravenous compared to oral busulfan with cyclophosphamide for autologous hematopoietic cell transplant conditioning for plasma cell myeloma. Hematology/ Oncology and Stem Cell Therapy, 2018, 11, 253-256.	0.9	0
29	Long-Term Outcomes after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia. Blood, 2015, 126, 5534-5534.	1.4	0
30	Comparative Effectiveness of Fludarabine and Busulfan Versus Fludarabine and 400 cGy Total Body Irradiation Reduced Intensity Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation for AML/MDS. Blood, 2015, 126, 1920-1920.	1.4	0
31	The Impact of Lockdown in England on Daily Confirmed Cases of COVID-19 and Related Deaths Compared to Sweden: A Comparative Interrupted Time Series Analysis. SSRN Electronic Journal, 0, , .	0.4	0
32	The Impact of IDH1c.315C>T Single Nucleotide Polymorphism on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study. Blood, 2021, 138, 4454-4454.	1.4	0
33	Pim Kinase Inhibitor Enhances FLT3 Inhibitor Efficacy through GSK-3Î ² Activation and GSK-3Î ² -Mediated Proteasomal Degradation of c-Myc. Blood, 2021, 138, 1163-1163.	1.4	0
34	Patterns of Treatment and Survival in Elderly Patients with Primary CNS Lymphoma; An 11-Year Population-Based Analysis. Blood, 2020, 136, 2-3.	1.4	O